Infliximab in dermatological treatment: beyond psoriasis

Bibliography

• Scheinfeld N. Off-label uses and side effects of infliximab. J Drugs Dermatol 2004;3(3):273-84
   PubMedGoogle Scholar
• CBER Approval Letter, for Infliximab for the treatment of moderately to severely active Crohn's disease, Centocor, Inc. Available from: URL: www.fda.gov/cder/foi/appletter/1998/inflcen082498L.htm [last accessed 6 August 2007]
   Google Scholar
• FDA. Remicade® Approval History. Available from: URL: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist [last accessed 15 November 2007]
   Google Scholar
• European Medicines Agency (EMEA). Available from: URL: www.emea.europa.eu/pdfs/human/press/pr/22946005en.pdf [last accessed 6 August 2007]
   Google Scholar
• Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg 2004;8(2):77-89
   PubMed Web of Science ®Google Scholar
• Bedini C, Nasorri F, Girolomoni G, De Pita O, Cavani A. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007;157:249-58
   PubMed Web of Science ®Google Scholar
• Waetzig GH, Schreiber S. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 2004;10:S38-S43
   PubMed Web of Science ®Google Scholar
• Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg 2004;8(4):224-8
   PubMed Web of Science ®Google Scholar
• Pereira TM, Vieira AP, Fernandes JC, Antunes H, Basto AS. Anti-TNF-α therapy in childhood pustular psoriasis. Dermatology 2006;213(4):350-2
   PubMed Web of Science ®Google Scholar
• Heikkila H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol 2005;141(12):1607-10
   PubMed Web of Science ®Google Scholar
• Lisby S, Gniadecki R. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol 2004;84(3):247-8
   PubMed Web of Science ®Google Scholar
• Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-α in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153(6):1243-4
   PubMed Web of Science ®Google Scholar
• Mang R, Ruzicka T, Stege H. Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-α inhibitor infliximab (Remicade). Br J Dermatol 2004;150(2):379-80
   PubMed Web of Science ®Google Scholar
• Bianchi L, Bergamin A, De Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005;52(4):736-7
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
   PubMed Web of Science ®Google Scholar
• Lopez-Robles E, Avalos-Diaz E, Vega-Memije E, et al. TNF-α and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001;40(3):185-8
   PubMed Web of Science ®Google Scholar
• Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005;153(1):222-3
   PubMed Web of Science ®Google Scholar
• Jacobi A, Schuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-α inhibitor infliximab. Br J Dermatol 2005;153(2):448-9
   PubMed Web of Science ®Google Scholar
• Hefferman MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol 2006;143(10):1268-70
   Google Scholar
• Bonifati C, Trento E, Cordiali Fei P, Muscardin L, Amantea A, Carducci M. Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids. Clin Exp Dermatol 2005;30(6):662-5
   PubMed Web of Science ®Google Scholar
• Meijer C, Huysen V, Smeenk RT, Swaak AJ. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993;2(6):359-65
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50(10):3161-9
   PubMed Web of Science ®Google Scholar
• Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007;56(1):274-9
   PubMed Web of Science ®Google Scholar
• Selva-O'callaghan A, Martinez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarrés M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 2004;43(9):1196-7
   PubMed Web of Science ®Google Scholar
• Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007;26(7):1186-8
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled trial of Remicade in primary Sjogren's syndrome (TRIPSS). Arthritis Rheum 2004;50(4):1270-6
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001;44(10):2371-75
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum 2002;46(12):3301-3
   PubMed Web of Science ®Google Scholar
• Foster EN, Nguyen KK, Sheikh RA, Prindiville TP. Crohn's disease associated with Sweet's syndrome and Sjögren's syndrome treated with infliximab. Clin Dev Immunol 2005;12(2):145-9
   PubMedGoogle Scholar
• Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor α blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64(2):262-6
   PubMed Web of Science ®Google Scholar
• Richez C, Dumoulin C, Coutouly X, Schaeverbeke T. Successful treatment of relapsing polychondritis with infliximab. Clin Exp Rheumatol 2004;22(5):629-31
   PubMed Web of Science ®Google Scholar
• Uthman IW, Touma Z, Sayyad J, Salman S. Response of deep cutaneous vasculitis to infliximab. J Am Acad Dermatol 2005;53(2):353-4
   PubMed Web of Science ®Google Scholar
• Connolly M, Armstrong JS, Buckley DA. Infliximab treatment for severe orogenital ulceration in Behcet's disease. Br J Dermatol 2005;153(5):1073-5
   PubMedGoogle Scholar
• Travis SPL, Czajkowski M, Mcgovern DPB, Watson RGP, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor α antibody. Gut 2001;49:725-8
   PubMed Web of Science ®Google Scholar
• Yucel AE, Kart-Koseoglu H, Akova YA, Demirhan B, Boyacioglu S. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease. Rheumatology (Oxford) 2004;43(4):394-6
   PubMed Web of Science ®Google Scholar
• Vega Gutierrez J, Rodriguez Prieto MA, Garcia Ruiz JM. Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol 2007;21(4):570-1
   PubMed Web of Science ®Google Scholar
• Della Rossa A, Tavoni A, Merlini G, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) 2005;44(8):1074-5
   PubMed Web of Science ®Google Scholar
• Kleinert J, Lorenz M, Köstler W, Hörl W, Sunder-Plassmann G, Soleiman A. Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr 2004;116:334-8
   PubMed Web of Science ®Google Scholar
• Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146(5):662-7
   PubMed Web of Science ®Google Scholar
• Tiliakos A IV, Shaia S, Hostoffer R, Kent L. The use of infliximab in a patient with steroid-dependent churg-strauss syndrome. J Clin Rheumatol 2004;10(2):96-97
   PubMed Web of Science ®Google Scholar
• Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 2006;25(1):109-10
   PubMed Web of Science ®Google Scholar
• Chandesris MO, Gayet S, Schleinitz N, Doudier B, Harle JR, Kaplanski G. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. Rheumatology (Oxford) 2004;43(4):532-3
   PubMed Web of Science ®Google Scholar
• Rahier JF, Lion L, Dewit O, Lambert M. Regression of Sweet's syndrome associated with Crohn's disease after anti-tumour necrosis factor therapy. Acta Gastroenterol Belg 2005;68(3):376-9
   PubMed Web of Science ®Google Scholar
• Bens G, Laharie D, Beylot-Barry M, et al. Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. Br J Dermatol 2003;149(1):181-4
   PubMed Web of Science ®Google Scholar
• Swale VJ, Saha M, Kapur N, Hoffbrand AV, Rustin HA. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol 2005;30(2):134-6
   PubMed Web of Science ®Google Scholar
• Brooklyn TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55(4):505-9
   PubMed Web of Science ®Google Scholar
• Shirakawa M, Uramoto K, Harada FA. Treatment of acne conglobata with infliximab. J Am Acad Dermatol 2006;55(2):344-6
   PubMed Web of Science ®Google Scholar
• Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003;149(5):1046-9
   PubMed Web of Science ®Google Scholar
• Usmani N, Clayton TH, Everett S, Goodfield MDH. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 2007;32(2):204-5
   PubMed Web of Science ®Google Scholar
• Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007;56(4):624-8
   PubMed Web of Science ®Google Scholar
• Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7(4):323-6
   PubMed Web of Science ®Google Scholar
• Olivieri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome. Expert Opin Investig Drugs 2006;15(10):1229-33
   PubMed Web of Science ®Google Scholar
• Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford) 2006;45(6):730-3
   PubMed Web of Science ®Google Scholar
• Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 2005;52:S118-S120
   PubMed Web of Science ®Google Scholar
• Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Persistent efficacy of tumor necrosis factor α blockage therapy in SAPHO syndrome: comment on the article by Wagner et al. Arthritis Rheum 2003;48(5):1467
   PubMed Web of Science ®Google Scholar
• Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 52(3 Pt 1):522-26
   PubMed Web of Science ®Google Scholar
• Manoharan S, White S, Gumparthy K. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol 2006;47(2):124-9
   PubMed Web of Science ®Google Scholar
• Lu R, George SJ, Hsu S. Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab. Dermatol Online J 2006;12(4):18
   PubMedGoogle Scholar
• Liao WC, Mutasim DF. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol 2005;141(4):423-5
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127(3):1064-71
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005;53(5):788-91
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174(7):795-802
   PubMed Web of Science ®Google Scholar
• Kolde G, Muche JM, Schulze P, Fischer P, Lichey J. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology 2003;206(2):180-1
   PubMed Web of Science ®Google Scholar
• Peitsch WK, Kemmler N, Goerdt S, Goebeler M. Infliximab: a novel treatment option for refractory orofacial granulomatosis. Acta Derm Venereol 2007;87(3):265-6
   PubMed Web of Science ®Google Scholar
• Kreuter A, Gambichler T, Altmeyer P. Infliximab therapy for interstitial granulomatous dermatitis. J Eur Acad Dermatol Venereol 2007;21(2):251-2
   PubMed Web of Science ®Google Scholar
• Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol 2005;141(9):1080-2
   PubMed Web of Science ®Google Scholar
• Hertl MS, Haendle I, Schuler G, Hertl M. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-α inhibitor, infliximab. Br J Dermatol 2005;152(3):552-5
   PubMed Web of Science ®Google Scholar
• Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 2006;31(6):823-4
   PubMed Web of Science ®Google Scholar
• Faber WR, Jensema AJ, Goldschmidt WFM. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med 2006;355(7):739
   PubMed Web of Science ®Google Scholar
• Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch WC, Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-α antibody infliximab: report of three cases. J Eur Acad Dermatol 2007;21(5):717-19
   Google Scholar
• Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146(4):707-9
   PubMed Web of Science ®Google Scholar
• Al-Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol 2005;85(6):534-5
   PubMed Web of Science ®Google Scholar
• Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 2005;25(6):406-10
   PubMed Web of Science ®Google Scholar
• Cardoso H, Nunes AC, Carneiro F, Tavarela Veloso F. Successful infliximab therapy for oral Crohn's disease. Inflamm Bowel Dis 2006;12(4):337-8
   PubMed Web of Science ®Google Scholar
• Rispo A, Lembo G, Insabato L, Cozzolino A, Pesce G, Castiglione F. Successful treatment of therapy-resistant metastatic Crohn's disease with infliximab. Br J Dermatol 2004;150(5):1045-6
   PubMed Web of Science ®Google Scholar
• Date RS, Panesar KJ, Neilly P. Infliximab as a therapy for non-Crohn's enterocutaneous fistulae. Int J Colorectal Dis 2004;19(6):603-6
   PubMed Web of Science ®Google Scholar
• Yang DJ, Hsu S. Infliximab treatment failure in a case of cutaneous Crohn's disease. J Am Acad Dermatol 2005;53(5):903-4
   PubMed Web of Science ®Google Scholar
• Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004;104(3):649-54
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Hallick J, Anders V, Mcmillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003;74:119-24
   PubMed Web of Science ®Google Scholar
• Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody. Bone Marrow Transplant 2001;28:47-49
   PubMed Web of Science ®Google Scholar
• Signal A, Janiga JJ, Bossenbroek NM, Lim HW. Dercum's disease (adiposis dolorosa): a report of improvement with infliximab and methotrexate. J Eur Acad Dermatol Venereol 2007;21(5):717
   Google Scholar
• Ortiz-Santamaria V, Valls-Roc M, Sanmarti M, Olive A. Anti-TNF treatment in secondary amyloidosis. Rheumatology (Oxford) 2003;42(11):1425-6
   PubMed Web of Science ®Google Scholar
• Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Familial Mediterranean Fever and its effect on secondary AA amyloidosis. J Clin. Rheumatol 2004;10(3):134-7
   PubMed Web of Science ®Google Scholar
• Lee MW, Lee EY, Jeong YI, Choi JH, Moon KC, Koh JK. Successful treatment of multicentric reticulohistiocytosis with a combination of infliximab, prednisolone and methotrexate. Acta Derm Venereol 2004;84(6):478-9
   PubMed Web of Science ®Google Scholar
• Bullimore DW. Endometriosis is sustained by tumour necrosis factor-alpha. Med Hypotheses 2003;60(1):84-88
   PubMed Web of Science ®Google Scholar
• Streit M, Beleznay Z, Braathen LR. Topical application of the tumour necrosis factor-α antibody infliximab improves healing of chronic wounds. Int Wound J 2006;3(3):171-9
   PubMedGoogle Scholar
• Remicade® (infliximab) Biologic Treatment. Available from: URL: www.remicade.com/remicade/global/index.html [last accessed 5 September 2007]
   Google Scholar
• Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity and associated infusion reactions. Mt Sinai J Med 2005;72(4):250-6
   PubMed Web of Science ®Google Scholar
• Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24(11):1720-40
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348(7):601-8
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson El, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar
• Geborek P, Bladström A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64(5):699-703
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50(6):1740-51
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345(15):1098-104
   PubMed Web of Science ®Google Scholar
• Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007;52(6):1481-4
   PubMed Web of Science ®Google Scholar
• Farah R, Lisitsin S, Shay M. Bacterial meningitis associated with infliximab. Pharm World Sci 2006;28(3):123-5
   PubMed Web of Science ®Google Scholar
• Matzkies FG, Manger B, Schmitt-Haendle M, et al. Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis 2003;62(1):81-82
   PubMed Web of Science ®Google Scholar
• Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53(9):1363-5
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138(10):807-11
   PubMed Web of Science ®Google Scholar
• Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Br J Dermatol 2007;156(3):486-91
   PubMed Web of Science ®Google Scholar
• Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005;20(7):1400-6
   PubMed Web of Science ®Google Scholar
• De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7(3):R545-R551
   PubMed Web of Science ®Google Scholar
• Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV Jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002;8(3):186-91
   PubMed Web of Science ®Google Scholar
• Strong BYC, Erny BC, Herzenberg H, Razzeca KJ. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease. Ann Intern Med 2004;140(8):W34
   PubMedGoogle Scholar
• Ruiz-Jimeno T, Carvajal A, Mata C, Aurrecoechea E. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. J Rheumatol 2006;33(7):1457-8
   PubMed Web of Science ®Google Scholar
• Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73(6):710-13
   PubMed Web of Science ®Google Scholar